Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 June 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Sulphonamide resistance in E. coli remains high, despite prescribing restriction

A substantial decrease in prescribing sulphonamides in the UK over the past decade has failed to reduce resistance to this class of antibiotics, conclude authors of a study in this week's issue of the Lancet.

News image

fiogf49gjkf04

There is a clear link between heavy antimicrobial use and the emergence of resistant bacteria. Whether a reduction in antimicrobial use can reverse this process is less certain.

Lucinda Hall, and David Livermore, and colleagues from St Bartholomew's and The Royal London School of Medicine and Dentistry, and the Central Public Health Laboratory, England, investigated the effect of the 1995 national restriction of sulphonamide prescribing in the UK on the prevalence of sulphonamide resistance in Escherichia coli.

Over 350 clinical isolates of E. coli were collected in 1991 and 1999, and the presence and locations of sulphonamide-resistance genes were assessed.

Frequency of E. coli sulphonamide resistance:
1991: 40%
1999: 46%
Lancet

Despite a huge decrease in sulphonamide prescriptions - from 3,208,000 prescriptions in 1991 to 77,000 in 1999 - the frequency of resistance remained high (165/359 [46%] in 1999 compared with 143/360 [40%] in 1991).

The prevalence of one specific resistance gene (SUL II) increased from 27% in 1991 to 36.5% in 1999.

Lucinda Hall comments, "We would like to think that if we stop using an antibiotic so much, resistance will go away, and we'll be able to use it again.

"Our study shows that we can't depend on this happening - once resistance to an antibiotic is common, it is going to be very difficult to get rid of. In part, this is because the genes that cause resistance to disused drugs, like sulphonamides, are linked to those that cause resistance to antibiotics we continue to use."

David Livermore adds, "Nevertheless, using antibiotics more carefully should slow the development of new resistance; and this - coupled with the development of new drugs - is vital if we are to keep ahead of the bacteria".

In an accompanying Commentary, Burke Cunha from Winthrop-University Hospital, Mineola, New York, USA, comments that the antibiotic resistance observed in Hall and colleagues' study is unsurprising. This is because the sulphonamide-restriction programme did not restrict the use of other antibiotics with high resistance potential commonly used in general practice, such as tetracycline and ampicillin.

Lancet 2001; 357 (9265): 1307, 1325
27 April 2001

Go to top of page Email this page Email this page to a colleague

 31 May 2018 
Diagnostic for NAFLD  
 31 May 2018 
Bile acids and the risks for hepatotoxicity
 31 May 2018 
Rectal cancer female sexuality score
 30 May 2018 
Fungal dysbiosis in cirrhosis
 30 May 2018 
Placebo rates in ulcerative colitis trials
 30 May 2018 
Follow-up testing and colorectal cancer mortality
 29 May 2018 
Organ transplantation donors
 29 May 2018 
Novel therapies for IBD
 29 May 2018 
Helicobacter pylori infection to stomach cancer
 28 May 2018 
Mesalazine in ulcerative colitis
 28 May 2018 
Technology and management of digestive diseases
 28 May 2018 
Therapeutic strategies for HCV
 25 May 2018 
Post‐operative complications in elderly IBD
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Colorectal cancer–specific mortality
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Chronic Hep B
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Symptom assessment in cirrhotic ascites
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
European guidelines on pancreatic cystic neoplasms

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us